SFM
Sphera Funds Management Portfolio holdings
AUM
$382M
This Quarter Return
-8.88%
1 Year Return
+0.41%
3 Year Return
+99.29%
5 Year Return
+177.09%
10 Year Return
+575.73%
AUM
$568M
AUM Growth
+$568M
(-15%)
Cap. Flow
-$10.3M
Cap. Flow
% of AUM
-1.81%
Top 10 Holdings %
Top 10 Hldgs %
41.82%
Holding
155
New
29
Increased
27
Reduced
41
Closed
33
Top Buys
| 1 |
Teva Pharmaceuticals
TEVA
|
$32.5M |
| 2 |
Elbit Systems
ESLT
|
$29.2M |
| 3 |
Incyte
INCY
|
$11M |
| 4 |
CEL
Cellcom Israel, Ltd.
CEL
|
$8.79M |
| 5 |
Biogen
BIIB
|
$7.08M |
Top Sells
| 1 |
Merck
MRK
|
$22.8M |
| 2 |
Gilead Sciences
GILD
|
$19.6M |
| 3 |
Pfizer
PFE
|
$9.42M |
| 4 |
CXRX
Concordia International Corp. Common Stock
CXRX
|
$9.03M |
| 5 |
Verint Systems
VRNT
|
$8.47M |
Sector Composition
| 1 | Healthcare | 76.98% |
| 2 | Industrials | 5.61% |
| 3 | Utilities | 3.5% |
| 4 | Technology | 1.75% |
| 5 | Consumer Discretionary | 1.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AGN
1
DELISTED
Allergan plc
AGN
| $48.1M | 6.14% | 177,100 | – | – |
|
|
2
Teva Pharmaceuticals
TEVA
$21.1B
| $42.5M | 5.42% | 752,905 +575,605 | +325% | +$32.5M |
|
|
3
Elbit Systems
ESLT
$22.3B
| $29.2M | 3.72% | +100,618 | New | +$29.2M |
|
|
4
Biogen
BIIB
$19.4B
| $24.8M | 3.16% | 85,000 +24,270 | +40% | +$7.08M |
|
|
5
Pfizer
PFE
$141B
| $18M | 2.3% | 574,013 -300,000 | -34% | -$9.42M |
|
6
AbbVie
ABBV
$372B
| $17.8M | 2.27% | 327,000 -80,000 | -20% | -$4.35M |
|
7
Ormat Technologies
ORA
$5.56B
| $17.6M | 2.24% | 132,659 +52,567 | +66% | +$6.95M |
|
|
SHPG
8
DELISTED
Shire pic
SHPG
| $13.3M | 1.69% | 169,751 +35,000 | +26% | +$2.73M |
|
9
BioMarin Pharmaceuticals
BMRN
$11.2B
| $13.2M | 1.68% | 125,000 +65,000 | +108% | +$6.85M |
|
|
CELG
10
DELISTED
Celgene Corp
CELG
| $13M | 1.66% | 120,000 -40,000 | -25% | -$4.33M |
|
|
11
Gilead Sciences
GILD
$140B
| $11.8M | 1.5% | 120,000 -200,000 | -63% | -$19.6M |
|
|
12
Incyte
INCY
$16.5B
| $11M | 1.41% | +100,000 | New | +$11M |
|
|
CLVS
13
DELISTED
Clovis Oncology, Inc.
CLVS
| $9.66M | 1.23% | 105,000 -15,000 | -13% | -$1.38M |
|
14
Bristol-Myers Squibb
BMY
$96B
| $8.88M | 1.13% | 150,000 +50,000 | +50% | +$2.96M |
|
|
CEL
15
DELISTED
Cellcom Israel, Ltd.
CEL
| $8.79M | 1.12% | +357,452 | New | +$8.79M |
|
16
Viatris
VTRS
$12.3B
| $8.05M | 1.03% | 200,000 +25,000 | +14% | +$1.01M |
|
|
ACOR
17
DELISTED
Acorda Therapeutics, Inc.
ACOR
| $7.16M | 0.91% | 270,000 +120,000 | +80% | +$3.18M |
|
18
Amgen
AMGN
$155B
| $6.94M | 0.89% | 50,200 -10,000 | -17% | -$1.38M |
|
19
Assertio
ASRT
$80.4M
| $6.79M | 0.87% | 360,000 +180,000 | +100% | +$3.39M |
|
20
Consumer Discretionary Select Sector SPDR Fund
XLY
$23.2B
| $6.63M | 0.85% | +89,216 | New | +$6.63M |
|
21
Vanda Pharmaceuticals
VNDA
$279M
| $5.79M | 0.74% | 513,390 | – | – |
|
22
Check Point Software Technologies
CHKP
$20.7B
| $5.74M | 0.73% | 72,327 -18,760 | -21% | -$1.49M |
|
|
ALXN
23
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $5.47M | 0.7% | +35,000 | New | +$5.47M |
|
|
TSRO
24
DELISTED
TESARO, Inc.
TSRO
| $4.71M | 0.6% | 117,500 +30,000 | +34% | +$1.2M |
|
25
Amicus Therapeutics
FOLD
$2.34B
| $4.34M | 0.55% | 310,000 -140,000 | -31% | -$1.96M |
|